[1] [9] Retatrutide is an investigational triple receptor agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
The health benefits for infants, reduced infections, improved immune function, potential long-term metabolic benefits, are well established
While the FDA often exercises enforcement discretion for a small supply of some medications, GLP-1s are different
15,16,17,20,21AsparagineThis amino acid is part of the structure ofthyroid stimulating hormone which regulatescommunication with other hormones
Injectable, 2015 to 2025 Exhibit 130: Generic Drug Approvals, FDA, 2014 to 2025 Exhibit 131: National Opioid Settlement Payments, by Company, 2025 Exhibit 132: Vertical Business Relationships Within the U.S